Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA: Canada Impact+ Research Training Awards - Doctoral

University of Ottawa

$120,000.00

Polyclonal allogeneic CAR-gd T cells for B lymphoma therapy

EF 2025-26

Résumé
"A revolutionary immune therapy called Chimeric Antigen Receptor (CAR) alpha beta (¿¿¿¿) T-cell therapy has transformed the treatment of blood cancers, enabling many patients to achieve complete remission. This approach involves reprogramming a patient’s own immune cells to better recognize and destroy cancer cells. However, nearly half of patients experience relapse within a year, and some face severe, potentially life-threatening side effects. Our research focuses on a new approach using a special type of immune cell called gamma-delta (¿¿¿¿) T cells. Unlike traditional ¿¿¿¿ T cells, ¿¿¿¿ T cells can attack cancer cells without needing a perfect match to the patient’s tissue type. This means we can use healthy donor cells, which are stronger and less worn out than the patient’s own cells. ¿¿¿¿ T cells are powerful killers of leukemia and lymphoma cells and release helpful signaling molecules that boost the immune response. They also show fewer dangerous side effects, making them safer for patients. We aim to engineer ¿¿¿¿ T cells with CARs, synthetic receptors designed to target specific cancer markers, creating an “off-the-shelf” therapy that can be given to many patients without the need for individual customization. This next-generation treatment could improve outcomes, reduce relapse rates, and minimize toxic side effects, positioning Canada at the forefront of innovative cancer immunotherapy."
Programme
DRA: Canada Impact+ Research Training Awards - Doctoral
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
568194
Name
Chen Tuanjie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Canada Impact+ Research Training Awards - Doctoral
Projecttitle
Polyclonal allogeneic CAR-gd T cells for B lymphoma therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA: Canada Impact+ Research Training Awards - Doctoral
Keyworddelim
Car-T Cell; Immunity; Lymphoma; T Cells
Abstract
"A revolutionary immune therapy called Chimeric Antigen Receptor (CAR) alpha beta (¿¿¿¿) T-cell therapy has transformed the treatment of blood cancers, enabling many patients to achieve complete remission. This approach involves reprogramming a patient’s own immune cells to better recognize and destroy cancer cells. However, nearly half of patients experience relapse within a year, and some face severe, potentially life-threatening side effects. Our research focuses on a new approach using a special type of immune cell called gamma-delta (¿¿¿¿) T cells. Unlike traditional ¿¿¿¿ T cells, ¿¿¿¿ T cells can attack cancer cells without needing a perfect match to the patient’s tissue type. This means we can use healthy donor cells, which are stronger and less worn out than the patient’s own cells. ¿¿¿¿ T cells are powerful killers of leukemia and lymphoma cells and release helpful signaling molecules that boost the immune response. They also show fewer dangerous side effects, making them safer for patients. We aim to engineer ¿¿¿¿ T cells with CARs, synthetic receptors designed to target specific cancer markers, creating an “off-the-shelf” therapy that can be given to many patients without the need for individual customization. This next-generation treatment could improve outcomes, reduce relapse rates, and minimize toxic side effects, positioning Canada at the forefront of innovative cancer immunotherapy."
Competitiondate
202603
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chen, Tuanjie
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~